Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

2.685 -0.015 (-0.56%)
Streaming Delayed Price Updated: 11:56 AM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,746
Open 2.600
Bid (Size) 2.570 (2)
Ask (Size) 2.800 (6)
Prev. Close 2.700
Today's Range 2.460 - 2.685
52wk Range 2.000 - 20.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
From Purple Biotech Ltd.
Via GlobeNewswire

Performance

YTD
-41.5%
-41.5%
1 Month
+1.3%
+1.3%
3 Month
-12.3%
-12.3%
6 Month
-2.0%
-2.0%
1 Year
-82.9%
-82.9%

More News

Read More
Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
From Purple Biotech Ltd.
Via GlobeNewswire
Why Purple Biotech (PPBT) Stock Is Getting Hammered
Via Benzinga
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom
Via Stocktwits
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Purple Biotech Stock Trading Higher On Monday?
Via Benzinga
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
From Purple Biotech Ltd.
Via GlobeNewswire
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
From Purple Biotech Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Purple Biotech Ltd. - American Depositary Shares publicly traded?
Yes, Purple Biotech Ltd. - American Depositary Shares is publicly traded.
What exchange does Purple Biotech Ltd. - American Depositary Shares trade on?
Purple Biotech Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Purple Biotech Ltd. - American Depositary Shares?
The ticker symbol for Purple Biotech Ltd. - American Depositary Shares is PPBT on the Nasdaq Stock Market
What is the current price of Purple Biotech Ltd. - American Depositary Shares?
The current price of Purple Biotech Ltd. - American Depositary Shares is 2.685
When was Purple Biotech Ltd. - American Depositary Shares last traded?
The last trade of Purple Biotech Ltd. - American Depositary Shares was at 06/05/25 11:56 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.